Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 12, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome
View HTML
Toggle Summary Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI , which is planned to be the site of an approximately 140,000 square foot
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 17, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 30, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 4th Annual Evercore ISI HealthCONx Conference December 2, 2021 , 1:00 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
- Conference Call and Webcast Today, November 22, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 22, 2021-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2021 . The company is hosting a conference call today,
View HTML
Toggle Summary Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
- Upon closing, Arrowhead to receive $120 million upfront payment for Phase 1/2 program for NASH - Arrowhead eligible to receive potential milestone payments and royalties on commercial sales - GSK to receive an exclusive license for ARO-HSD in all territories except Greater China PASADENA, Calif.
View HTML
Toggle Summary Arrowhead Announces JNJ-75220795 in Development for NASH
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 17, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that its collaborator, Janssen Pharmaceuticals, Inc. , (Janssen) one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has disclosed its collaboration with Arrowhead on
View HTML
Toggle Summary Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) collaborator Janssen Pharmaceuticals, Inc. , one of the Janssen Pharmaceutical Companies of Johnson & Johnson, presented clinical data from REEF-1, a Phase 2b study of different combination regimens,
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional Phase 1/2 clinical data on ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment
View HTML